[MARKET UPDATE] US indices continue to slip further into the red, with tech leading the downside; NQ -1.8%, NVIDIA now -3.5%, despite opening higher by c. 2%
Newsquawk Staff ·
US indices continue to slip further into the red, with tech leading the downside; NQ -1.8%, NVIDIA now -3.5%, despite opening higher by c. 2%.
What it means
A reversal of this shape, where the opening bid in the single most crowded name fails and the stock travels several percent from green to deep red within the session, has historically carried more signal than the magnitude itself, since it indicates selling into strength rather than a mere absence of buyers. Episodes in which the market's leadership cohort fades an opening gap while the broader tape slips have tended to cluster in two setups: corrective phases within an uptrend, where prior winners absorb profit-taking first and breadth deteriorates from the top down, and event-driven de-risking ahead of scheduled catalysts, where positioning is trimmed into the strongest names because that is where the liquidity is. The distinction worth watching is whether the weakness is confined to the high-beta leadership complex or is broadening into defensives and equal-weight measures; the former fits the consolidation pattern, the latter is how wider drawdowns have typically begun. The tells from here are the intraday sequence rather than the level: whether the lows are retested into the close, whether the cash close confirms or recovers the morning damage, and whether the semis peer set follows the leader or holds. Follow-ons of note are the tone of any end-of-session commentary and the next day's open, since failed gaps in a leadership name have historically been tested quickly in either direction.
- Newsquawk European Market Wrap - 13th November 2026
- US EQUITY OPEN: Indices pare gains as Tech once again underperforms
- Daily US Equity Opening News: MSFT outage recovery continues; ANT IPO 6x oversubscribed; NSCL needs more financing for ANT deal
- US Broker Moves: PANW upgraded at KeyBanc; AVGO downgraded at Rothschild Redburn
- [MARKET ANALYSIS] Asia-Pac stocks are mixed in the Nvidia fallout and following Huang's resignation
Related headlines
- [MARKET ANALYSIS] Dollar takes a breather in uneventful FX trade and after strengthening again yesterday12 hours ago
- [MARKET ANALYSIS] T-note futures remain lacklustre after the prior day's bear flattening13 hours ago
- [MARKET ANALYSIS] Oil prices mildly pulled back after climbing yesterday on less encouraging US-Iran headlines13 hours ago
- [MARKET UPDATE] Asia-Pac stocks begin mixed following the ultimately negative and choppy performance stateside amid the fallout from Nvidia and Jensen Huang's resignation15 hours ago
- Newsquawk Daily Asia-Pac Opening News - 13th November 202617 hours ago
- OpenAI starts ChatGPT wallet, available to Pro subscribers, CNBC reports31 min ago
- Newsquawk Weekly Economic Release 16th - 20th November 202637 min ago
- Week in Focus – 16-20th November 2026: Highlights include: US Retail Sales, FOMC Minutes, Chinese Activity Data, PBoC LPR, RBA Minutes, UK Inflation and UK Jobs1 hour ago
- SpaceX's (SPCX) AI group reportedly cuts around 60 Grok video generation staff, The Information reports citing sources; the co. has prioritised AI coding tools and Grok bot 1 hour ago
- US Treasury Secretary Bessent says it was clear China shouldn’t receive any chips more advanced than H100s (NVDA); Treasury has been pushing for export controls and for Megaspeed to be added to the Entity List for months;2 hours ago
- Microsoft (MSFT), on the outage, says recovery keeps progressing across affected regions, with wider improvements now seen in North America and much of Europe2 hours ago
- PRIMER – Today’s Fedspeak includes: Goolsbee, Collins, Logan, Bowman, Daly, Jefferson3 hours ago
- PREVIEW - US October PPI data will be released at 13:30GMT/08:30EST3 hours ago
- Manchester United (MANU) appoint Mauricio Pochettino as Head Coach3 hours ago
- Merck (MRK) says WELIREG in combination with lenvatinib demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, one of the study's dual primary endpoints, for treatment of ccRCC4 hours ago